Compare Cassava Sciences Inc (FLNA) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Sirius XM Holdings Inc — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while Sirius XM Holdings Inc trades at $31.26 (market cap $10.32B). The key difference: Sirius XM Holdings Inc is far larger — about 194.2× Cassava Sciences Inc's market cap, and Sirius XM Holdings Inc pays a 3.52% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | SIRI | |
|---|---|---|
Market Cap | $53.14M | $10.32B |
Sector | Health | Media |
52-Week High | $4.64 | $30.75 |
52-Week Low | $1.09 | $19.92 |
Enterprise Value | -$33.43M | $19.99B |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Sirius XM Holdings (SIRI) trades at $30.39, down 0.91% on the day, with strong technical momentum indicated by bullish moving averages. The company has beaten earnings expectations for three consecutive quarters, with Q2 2026 results due July 30. Recent developments include a strategic ad tech partnership with YouTube and potential inclusion in the S&P MidCap 400, driving positive investor sentiment.
The outlook remains positive with analyst consensus at Buy (58%) and $31.17 price target. Strong cash flow generation supports dividends and buybacks, though high debt levels and competitive pressures in media streaming present ongoing risks. Recent return to profitability after 2024's net loss positions SIRI for sustained growth if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
